| Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori RA Alm, LSL Ling, DT Moir, BL King, ED Brown, PC Doig, DR Smith, ... Nature 397 (6715), 176-180, 1999 | 2456 | 1999 |
| EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations MT McCabe, HM Ott, G Ganji, S Korenchuk, C Thompson, GS Van Aller, ... Nature 492 (7427), 108-112, 2012 | 1940 | 2012 |
| Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase C Vickers, P Hales, V Kaushik, L Dick, J Gavin, J Tang, K Godbout, ... Journal of Biological Chemistry 277 (17), 14838-14843, 2002 | 1902 | 2002 |
| Residence time of receptor− ligand complexes and its effect on biological function PJ Tummino, RA Copeland Biochemistry 47 (20), 5481-5492, 2008 | 626 | 2008 |
| Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) MT McCabe, AP Graves, G Ganji, E Diaz, WS Halsey, Y Jiang, ... Proceedings of the National Academy of Sciences 109 (8), 2989-2994, 2012 | 560 | 2012 |
| A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC HP Mohammad, KN Smitheman, CD Kamat, D Soong, KE Federowicz, ... Cancer cell 28 (1), 57-69, 2015 | 520 | 2015 |
| Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin SD Knight, ND Adams, JL Burgess, AM Chaudhari, MG Darcy, ... ACS Medicinal Chemistry Letters 1 (1), 39-43, 2010 | 418 | 2010 |
| SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer PK Mazur, N Reynoird, P Khatri, PWTC Jansen, AW Wilkinson, S Liu, ... Nature 510 (7504), 283-287, 2014 | 415 | 2014 |
| Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2 SK Verma, X Tian, LV LaFrance, C Duquenne, DP Suarez, KA Newlander, ... ACS medicinal chemistry letters 3 (12), 1091-1096, 2012 | 415 | 2012 |
| Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors R Kumar, MC Crouthamel, DH Rominger, RR Gontarek, PJ Tummino, ... British journal of cancer 101 (10), 1717-1723, 2009 | 251 | 2009 |
| Helicobacter pylori Physiology Predicted from Genomic Comparison of Two Strains P Doig, BL de Jonge, RA Alm, ED Brown, M Uria-Nickelsen, B Noonan, ... Microbiology and Molecular Biology Reviews 63 (3), 675-707, 1999 | 243 | 1999 |
| BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models A Wyce, G Ganji, KN Smitheman, C Chung, S Korenchuk, Y Bai, ... PloS one 8 (8), e72967, 2013 | 228 | 2013 |
| Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762 A Chaidos, V Caputo, K Gouvedenou, B Liu, I Marigo, MS Chaudhry, ... Blood, The Journal of the American Society of Hematology 123 (5), 697-705, 2014 | 227 | 2014 |
| Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors NA Dales, AE Gould, JA Brown, EF Calderwood, B Guan, CA Minor, ... Journal of the American Chemical Society 124 (40), 11852-11853, 2002 | 221 | 2002 |
| Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation GS Van Aller, N Reynoird, O Barbash, M Huddleston, S Liu, AF Zmoos, ... Epigenetics 7 (4), 340-343, 2012 | 210 | 2012 |
| Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer A Wyce, Y Degenhardt, Y Bai, BC Le, S Korenchuk, MC Crouthamel, ... Oncotarget 4 (12), 2419, 2013 | 207 | 2013 |
| Cancer epigenetics drug discovery and development: the challenge of hitting the mark RM Campbell, PJ Tummino The Journal of clinical investigation 124 (1), 64-69, 2014 | 188 | 2014 |
| Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor GS Van Aller, JD Carson, W Tang, H Peng, L Zhao, RA Copeland, ... Biochemical and biophysical research communications 406 (2), 194-199, 2011 | 187 | 2011 |
| Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a … DA Heerding, N Rhodes, JD Leber, TJ Clark, RM Keenan, LV Lafrance, ... Journal of medicinal chemistry 51 (18), 5663-5679, 2008 | 179 | 2008 |
| Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase JD Carson, G Van Aller, R Lehr, RH Sinnamon, RB Kirkpatrick, KR Auger, ... Biochemical Journal 409 (2), 519-524, 2008 | 156 | 2008 |
